Abstract
Aging is associated with numerous alterations in body composition and organ function that result in substantial changes in the absorption, distribution, metabolism, and elimination of virtually all drugs. In addition, older patients with heart failure (HF) almost invariably have multiple coexisting medical conditions for which they are receiving medications. This article reviews common adverse drug effects and drug interactions associated with HF therapy in older patients and discusses strategies for reducing the risk of adverse drug events. In order to minimize these risks, it is essential that clinicians avoid prescribing unnecessary medications, adjust medication dosages to optimally balance benefits and side effects, and remain ever vigilant to the potential for medications to cause or contribute to clinically important adverse events and impaired quality of life. In treating older HF patients, the oft-cited dictum “start low, go slow” clearly applies. Despite the inherent challenges, with careful management and close follow-up, most older HF patients can be successfully treated through the judicious use of guideline-recommended HF therapies.
Similar content being viewed by others
References
Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398
Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76
Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233
Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141
Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124
Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340
Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720
Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532
Shem S (1979) House of God. Random House, Inc, New York
Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601
Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752
Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470
Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171
Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318
Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551
Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978
Braunstein GD (2007) Clinical practice. Gynecomastia. N Engl J Med 357:1229–1237
Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479
Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354
Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497
Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362
Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186
Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813
Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280
Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914
Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419
Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97
Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644
Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494
Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24S
Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784
Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322
Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582
Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878
Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253
Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223
Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14
Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146
Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847
Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108
Wick JY, LaFleur J (2007) Fatigue: implications for the elderly. Consult Pharm 22:566–578
Choi JY, Morris JC, Hsu CY (1998) Aging and cerebrovascular disease. Neurol Clin 16:687–711
Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554
Conflict of interest
Sanofi-Aventis—consultant; speaker’s bureau, Astellas Pharma US—small project grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rich, M.W. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev 17, 589–595 (2012). https://doi.org/10.1007/s10741-011-9263-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-011-9263-1